6:22 PM
 | 
Mar 10, 2008
 |  BC Extra  |  Top Story

Keryx falls on Sulonex data

Keryx (NASDAQ:KERX) fell $4.62 (88%) to $0.64 on 46.6 million shares on Monday after Sulonex sulodexide missed the primary endpoint of a significant increase in therapeutic success rate at six months vs. placebo in the Phase III SUN-MICRO trial to treat diabetic nephropathy. Success in...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >